Using Santyl on Diabetic Foot Ulcers

NCT ID: NCT01408277

Last Updated: 2014-07-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-08-31
• Study Completion Date: 2013-03-31

Brief Summary

Subjects enrolled in this study will either use Santyl daily or follow standard care procedures for up to 6 weeks for their diabetic foot wound. After 6 weeks of treatment, the subjects will continue into the follow-up phase for an additional 6 weeks. Study doctors will look at the wound in the office each week (up to 12 weeks) to see if the wound is healing. Depending on a number of factors at each office visit, the study doctors may also use a procedure called sharp debridement to remove dead skin from the wound.

This study will test the hypothesis that daily treatment of diabetic foot wounds with Santyl will result in more rapid healing, healthier wounds, and fewer required sharp debridements over the study period than for diabetic foot wounds treated in other ways.

Conditions

Diabetic Foot Ulcers; Diabetic Foot Wounds

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Santyl

2mm Santyl applied once daily.

Group Type: ACTIVE_COMPARATOR

Santyl

Intervention Type: BIOLOGICAL

2 mm Santyl applied once daily

Control

Standard Care

Group Type: ACTIVE_COMPARATOR

Control

Intervention Type: PROCEDURE

Standard Care

Interventions

Santyl

2 mm Santyl applied once daily

Intervention Type: BIOLOGICAL

Control

Standard Care

Intervention Type: PROCEDURE

Other Intervention Names

Standard Care

Eligibility Criteria

Inclusion Criteria

• Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
• Subjects 18 years of age or older. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
• A target ulcer which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit) with a duration ≥ 30 days (documented in the patient's history or by patient report of onset) which requires sharp surgical debridement.
• Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.7 and ≤ 1.1. If the ABI is greater than 1.1, then a toe pressure of > 40 mmHg OR a TcPO2 ≥ 40 mmHg must be present. Either toe pressure or TcPO2 is also acceptable as a stand-alone measurement, but if both are obtained, each must meet its respective cutoff.
• Alternatively, a Doppler waveform consistent with adequate flow to the region of the foot with the target ulcer (biphasic or triphasic waveforms) is acceptable.
• A target ulcer that is not infected based on clinical assessment.
• Willing and able to make all required study visits.
• Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.
• Willing to use an appropriate off-loading device whenever necessary to keep weight off of any foot ulcers.
• History of diabetes mellitus (Type 1 or 2) requiring insulin or oral hypoglycemic medications to control blood glucose levels.
• CBC and blood chemistry values as follows:

• Serum albumin ≥ 2.0 g/dL
• Pre-albumin levels of ≥ 15 mg/dL
• Alkaline phosphatase ≤ 500 U/L
• Alanine aminotransferase (ALT) ≤ 200 U/L
• Aspartate aminotransferase (AST) ≤ 175 U/L
• Serum total bilirubin ≤ 3.0 mg/dL
• Serum BUN < 75 mg/dL
• Serum creatinine ≤ 4.5 mg/dL
• HbA1c ≤ 12%
• Hemoglobin (Hgb) > 8.0 g/dL
• WBC > 2.0 x 109/L
• Absolute neutrophil count > 1.0 x 109/L
• Platelet count > 50 x 109/L

Exclusion Criteria

• Contraindications or hypersensitivity to the use of the study medications or their components.
• Target ulcer does not require debridement.
• Uncontrolled bleeding disorder.
• Cellulitis of the target wound, lymphangitic streaking, deep tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.
• Infection with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, azotemia).
• Any of the following:

• Target ulcer tunneling
• Target ulcer requires hyperbaric or negative pressure therapy per the investigator's medical judgment
• Target ulcer is on the heel and cannot be offloaded
• Target ulcer is over a Charcot deformity which cannot be offloaded
• NOTE: A heel ulcer or an ulcer over a Charcot is not excluded unless effective offloading is not possible.
• Current, ongoing osteomyelitis of the target foot as determined by medical history.
• Participation in another investigational clinical study within thirty (30) days of the Screening Visit.
• A target ulcer which involves underlying tissues (i.e., fat, fascia, tendon, muscle, bone).
• A target ulcer on a non-neuropathic foot (neuropathic defined as inability to perceive 10 grams pressure using a Semmes-Weinstein 5.07 or equivalent monofilament in the periwound area).
• NOTE: Monofilament test result must be documented.
• Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.
• Current treatment (at the time of the Screening Visit) with any of the following:

• Systemic corticosteroids
• Immunosuppressive agents
• Chemotherapeutic agents
• Antiviral agents
• Platelet-derived growth factor (e.g., Regranex)
• Living skin equivalent (e.g., Apligraf)
• Dermal substitute (e.g., Dermagraft, Integra, etc.)
• Systemic antibiotic therapy or topical antibiotic treatment of the target ulcer
• Radiation therapy to the target lower extremity within 30 days prior to screening The Medical Monitor and/or Investigator may declare any subject ineligible for a valid medical reason.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Healthpoint

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Herbert B Slade, MD

Role: STUDY_CHAIR

Healthpoint

Locations

Associated Foot and Ankle Specialists

Phoenix, Arizona, United States

Aung Foothealth Clinics

Tucson, Arizona, United States

Foot Healthcare Associates, PC

Southfield, Michigan, United States

Overlook Hospital Wound Care Center

Summit, New Jersey, United States

UNTHSC Fort Worth

Fort Worth, Texas, United States

Robert Wunderlich

San Antonio, Texas, United States

Endeavor Clinical Trials

San Antonio, Texas, United States

Countries

United States

References

Motley TA, Gilligan AM, Lange DL, Waycaster CR, Dickerson JE Jr. Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial. J Foot Ankle Res. 2015 Feb 28;8:7. doi: 10.1186/s13047-015-0065-x. eCollection 2015.

Reference Type: DERIVED

PMID: 25767565 (View on PubMed)

Other Identifiers

017-101-09-030

Identifier Type: -

Identifier Source: org_study_id